{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Carcinoma&page=14",
    "query": {
      "condition": "Neuroendocrine Carcinoma",
      "page": 14
    },
    "page_size": 10
  },
  "pagination": {
    "page": 14,
    "page_size": 10,
    "total_count": 946,
    "total_pages": 95,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Carcinoma&page=15&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Carcinoma&page=13&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T10:51:55.186Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07285044",
      "title": "The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Amyloidosis",
        "Basal Cell Carcinoma",
        "Biliary Tract Carcinoma",
        "Bladder Carcinoma",
        "Breast Carcinoma",
        "Cervical Carcinoma",
        "Colorectal Carcinoma",
        "Endometrial Carcinoma",
        "Fallopian Tube Carcinoma",
        "Gastroesophageal Junction Carcinoma",
        "Glioblastoma",
        "Head and Neck Carcinoma",
        "Hematopoietic and Lymphatic System Neoplasm",
        "Hepatocellular Carcinoma",
        "Hodgkin Lymphoma",
        "Lung Carcinoma",
        "Malignant Solid Neoplasm",
        "Mantle Cell Lymphoma",
        "Melanoma",
        "Merkel Cell Carcinoma",
        "Multiple Myeloma",
        "Myelodysplastic Syndrome",
        "Ovarian Carcinoma",
        "Pancreatic Carcinoma",
        "Primary Peritoneal Carcinoma",
        "Prostate Carcinoma",
        "Renal Cell Carcinoma",
        "Squamous Cell Carcinoma",
        "Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Cancer Therapeutic Procedure",
          "type": "DRUG"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2025-12-18",
      "completion_date": "2027-05-15",
      "has_results": false,
      "last_update_posted_date": "2026-09-30",
      "last_synced_at": "2026-10-14T10:51:55.186Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07285044"
    },
    {
      "nct_id": "NCT00161187",
      "title": "Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "therapeutic allogeneic lymphocytes",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Medicine and Dentistry of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 37,
      "start_date": "2001-05",
      "completion_date": "2011-10",
      "has_results": false,
      "last_update_posted_date": "2015-11-06",
      "last_synced_at": "2026-10-14T10:51:55.186Z",
      "location_count": 1,
      "location_summary": "New Brunswick, New Jersey",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00161187"
    },
    {
      "nct_id": "NCT04276597",
      "title": "Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Neuroendocrine Neoplasm",
        "Pheochromocytoma",
        "Paraganglioma",
        "Thymus Carcinoid",
        "Unknown Primary Tumors",
        "Neuroendocrine Tumors",
        "Neuroendocrine Skin Carcinoma",
        "Neuroendocrine Breast Tumor",
        "Neuroendocrine Carcinoma Metastatic",
        "Neuroendocrine Neoplasm of Ovary"
      ],
      "interventions": [
        {
          "name": "177Lu-DOTATOC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Excel Diagnostics and Nuclear Oncology Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2020-03-04",
      "completion_date": "2021-07-15",
      "has_results": false,
      "last_update_posted_date": "2023-03-10",
      "last_synced_at": "2026-10-14T10:51:55.186Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04276597"
    },
    {
      "nct_id": "NCT02085070",
      "title": "MK-3475 in Melanoma and NSCLC Patients With Brain Metastases",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma",
        "Non-Small Cell Lung Cancer",
        "Brain Metastases"
      ],
      "interventions": [
        {
          "name": "MK-3475",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 65,
      "start_date": "2014-03",
      "completion_date": "2020-02-27",
      "has_results": true,
      "last_update_posted_date": "2021-03-24",
      "last_synced_at": "2026-10-14T10:51:55.186Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02085070"
    },
    {
      "nct_id": "NCT00423254",
      "title": "Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian",
        "Melanoma",
        "Renal",
        "Prostate",
        "Colorectal",
        "Endometrial Carcinoma",
        "Cervical Carcinoma",
        "Testicular Cancer",
        "Thyroid Cancer",
        "Small Cell Lung Carcinoma",
        "Mesothelioma",
        "Breast Carcinoma",
        "Esophageal Carcinoma",
        "Gastric Cancer",
        "Pancreatic Carcinoma",
        "Neuroendocrine Cancer",
        "Liver Cancer",
        "Gallbladder Cancer",
        "Biliary Tract Cancer",
        "Anal Carcinoma",
        "Bone Sarcomas",
        "Soft Tissue Sarcomas",
        "Carcinoma of Unknown Origin, Primary"
      ],
      "interventions": [
        {
          "name": "PSMA/PRAME",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Mannkind Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2007-02",
      "completion_date": "2009-11",
      "has_results": false,
      "last_update_posted_date": "2010-08-03",
      "last_synced_at": "2026-10-14T10:51:55.186Z",
      "location_count": 5,
      "location_summary": "Tuscon, Arizona • Washington D.C., District of Columbia • Tampa, Florida + 2 more",
      "locations": [
        {
          "city": "Tuscon",
          "state": "Arizona"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Sparks",
          "state": "Nevada"
        },
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00423254"
    },
    {
      "nct_id": "NCT01204476",
      "title": "Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gastrin-Producing Neuroendocrine Tumor",
        "Lung Carcinoid Tumor",
        "Metastatic Digestive System Neuroendocrine Tumor G1",
        "Pancreatic Glucagonoma",
        "Pancreatic Insulinoma",
        "Pancreatic Polypeptide Tumor",
        "Paraganglioma",
        "Recurrent Digestive System Neuroendocrine Tumor G1",
        "Recurrent Merkel Cell Carcinoma",
        "Recurrent Pancreatic Neuroendocrine Carcinoma",
        "Regional Digestive System Neuroendocrine Tumor G1",
        "Somatostatin-Producing Neuroendocrine Tumor",
        "Stage III Merkel Cell Carcinoma",
        "Stage IV Merkel Cell Carcinoma",
        "Thyroid Gland Medullary Carcinoma"
      ],
      "interventions": [
        {
          "name": "Cixutumumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Octreotide Acetate",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2010-10",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2016-07-15",
      "last_synced_at": "2026-10-14T10:51:55.186Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01204476"
    },
    {
      "nct_id": "NCT02893930",
      "title": "Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Neuroendocrine Tumor G1",
        "Pancreatic Neuroendocrine Tumor G2",
        "Refractory Pancreatic Neuroendocrine Carcinoma"
      ],
      "interventions": [
        {
          "name": "Sapanisertib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2017-04-28",
      "completion_date": "2022-12-21",
      "has_results": true,
      "last_update_posted_date": "2023-10-17",
      "last_synced_at": "2026-10-14T10:51:55.186Z",
      "location_count": 405,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Hot Springs, Arkansas + 260 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Arroyo Grande",
          "state": "California"
        },
        {
          "city": "Auburn",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02893930"
    },
    {
      "nct_id": "NCT03894618",
      "title": "SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Squamous Cell Carcinoma of the Head and Neck",
        "Melanoma",
        "Non Small Cell Lung Cancer",
        "Urothelial Carcinoma",
        "Gastric Adenocarcinoma",
        "Gastroesophageal Junction Adenocarcinoma",
        "Squamous Cell Carcinoma of the Anus",
        "Squamous Cell Carcinoma of the Cervix",
        "Squamous Cell Carcinoma of the Skin",
        "Renal Cell Carcinoma",
        "Hodgkin Lymphoma",
        "Diffuse Large B Cell Lymphoma",
        "Mismatch Repair Deficient or MSI-High Solid Tumors"
      ],
      "interventions": [
        {
          "name": "SL-279252",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shattuck Labs, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2019-03-26",
      "completion_date": "2023-05-04",
      "has_results": true,
      "last_update_posted_date": "2025-04-02",
      "last_synced_at": "2026-10-14T10:51:55.186Z",
      "location_count": 2,
      "location_summary": "Nashville, Tennessee • Houston, Texas",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03894618"
    },
    {
      "nct_id": "NCT05653882",
      "title": "A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor",
        "Non Small Cell Lung Cancer",
        "Melanoma",
        "Squamous Cell Carcinoma of Head and Neck",
        "Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "etakafusp alfa (AB248)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Asher Biotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 552,
      "start_date": "2023-01-04",
      "completion_date": "2027-05",
      "has_results": false,
      "last_update_posted_date": "2025-09-10",
      "last_synced_at": "2026-10-14T10:51:55.186Z",
      "location_count": 20,
      "location_summary": "Duarte, California • Los Angeles, California • San Diego, California + 15 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05653882"
    },
    {
      "nct_id": "NCT05215574",
      "title": "Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Cancer",
        "Breast Cancer",
        "Gastric Cancer",
        "Non-small Cell Lung Cancer",
        "Cervical Cancer",
        "Endocervical Cancer",
        "Squamous Cell Carcinoma of Head and Neck",
        "Bladder Urothelial Cancer",
        "Colorectal Carcinoma",
        "Esophageal Cancer",
        "Ovarian Cancer",
        "Renal Cell Carcinoma",
        "Prostate Cancer",
        "Melanoma",
        "Mesothelioma",
        "Cholangiocarcinoma"
      ],
      "interventions": [
        {
          "name": "NGM831",
          "type": "DRUG"
        },
        {
          "name": "NGM831 plus pembrolizumab (KEYTRUDA®)",
          "type": "DRUG"
        },
        {
          "name": "NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NGM Biopharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 130,
      "start_date": "2022-03-31",
      "completion_date": "2026-03",
      "has_results": false,
      "last_update_posted_date": "2024-10-10",
      "last_synced_at": "2026-10-14T10:51:55.186Z",
      "location_count": 9,
      "location_summary": "Gilbert, Arizona • Los Angeles, California • Sarasota, Florida + 6 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05215574"
    }
  ]
}